Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
145.4 USD | +1.48% | +4.75% | +41.81% |
06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
06-28 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Sales 2024 * | 292B 42.04B 57.46B | Sales 2025 * | 352B 50.81B 69.44B | Capitalization | 4,460B 643B 879B |
---|---|---|---|---|---|
Net income 2024 * | 104B 15.04B 20.56B | Net income 2025 * | 128B 18.45B 25.21B | EV / Sales 2024 * | 15.4 x |
Net Debt 2024 * | 22.58B 3.26B 4.45B | Net cash position 2025 * | 5.93B 855M 1.17B | EV / Sales 2025 * | 12.6 x |
P/E ratio 2024 * |
43.3
x | P/E ratio 2025 * |
35.2
x | Employees | 66,015 |
Yield 2024 * |
1.17% | Yield 2025 * |
1.44% | Free-Float | 70.22% |
Latest transcript on Novo Nordisk A/S
1 day | +1.48% | ||
1 week | +4.75% | ||
1 month | +8.34% | ||
3 months | +14.91% | ||
6 months | +41.81% | ||
Current year | +41.81% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 90-12-31 | |
Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 15-03-18 |
Helge Lund
CHM | Chairman | 62 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-28 | 145.4 | +1.48% | 3,193 |
24-06-27 | 143.2 | -1.74% | 23,266 |
24-06-26 | 145.8 | -2.13% | 41,718 |
24-06-25 | 149 | +4.53% | 5,567 |
24-06-24 | 142.5 | +2.70% | 1,697 |
Delayed Quote OTC Markets, June 28, 2024 at 03:58 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.32% | 815B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- NONOF Stock